About this information
Search the summaries of completed Access to Information (ATI) requests to find information about ATI requests made to the Government of Canada after January 2020. If you find a summary of interest, you can request a copy of the records at no cost using the form below each summary. Requests made through this form are considered informal requests and are not subject to the same requirements as requests under the Access to Information Act (ATIA).
If you don’t find what you are looking for you can request additional government records under an institution’s control by contacting the institution’s Access to Information and Privacy Coordinator or by submitting a formal access to information request.
*All information provided will incorporate the necessary exemptions and exclusions as per the Access to Information Act and the Privacy Act.
Download datasets of the summaries of completed access to information requests.
Current Search
Report Type
Organization
Disposition
Year
Month
Found 489 record(s)
Req # A-2021-001610
All records relating to proposals submitted to Health Canada for the Request for Proposal (RFP) titled National Strategy for Drugs and Rare Diseases under solicitation no. 1000233573 from November 15 2021 to December 17 2021.Organization: Health Canada
May 2023
Req # A-2022-000046
All records in possession of the Strategic Policy Branch of Health Canada regarding leasehold improvements and/or changes to capital assets of Canadian Agency for Drugs and Technologies in Health (CADTH) between April 1, 2019 and March 31, 2020.Organization: Health Canada
May 2023
Req # A-2022-000885
All records and communications to and from Mr. Morris Rosenberg by Health Canada from June 1st, 2021 to September 27, 2022.Organization: Health Canada
May 2023
Req # A-2022-000890
All records regarding oral contraceptive MYA (DIN 02415380) from January 1st, 2021, to September 1st, 2022.Organization: Health Canada
May 2023
Req # A-2022-001162
Health Canada premarket review and approval of the clinical trials for the antidpressant Effexor/venlafaxine.Organization: Health Canada
May 2023
Req # A-2022-001166
All emails to and from Twitter and Facebook employees since Jan 1, 2019.Organization: Health Canada
May 2023
Req # A-2022-001376
All correspondence between Health Canada Office of Pharmaceutical Management Strategies and the Patented Medicine Prices Review Board pertaining to the October 2022 revised draft Guidelines.Organization: Health Canada
May 2023
Req # A-2022-001415
Any internal or external communications from January 1, 2018 to December 31, 2022 involving the Minister of Health or a Health Canada employee at the level of Director General, Assistant Deputy Minister, Associate Deputy Minister, or Deputy Minister…Organization: Health Canada
May 2023
Req # A-2022-001494
The draft Product Monograph included in the New Drug Submission (NDS) for Captopril at the time of screening, any and all Notices of Deficiency, Notices of Non-Compliance and clarifaxes associated with Health Canada's review of the NDS.Organization: Health Canada
May 2023
Req # A-2022-001499
The initial cover letter indicating the brand name of the reference drug product and the dosage form of the generic drug in Health Canada’s list of “Generic Drug Submissions Under Review” dated 2023-02-24 for the medicinal ingredient aprepitant. The…Organization: Health Canada
May 2023